The Importance of Early Monitoring and Identification of Cardiotoxicity of Trastuzumab Treatment in Breast Cancer: Case Report
Autor(a) principal: | |
---|---|
Data de Publicação: | 2019 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | por eng |
Título da fonte: | Revista Brasileira de Cancerologia (Online) |
Texto Completo: | https://rbc.inca.gov.br/index.php/revista/article/view/570 |
Resumo: | Introduction: Breast cancer represents the most common neoplasm among women, with elevated morbimortality. With the appearance of new drugs, there has been an increase of global survival; however, trastuzumab, a monoclonal antibody used in the treatment, may promote cardiotoxicity that should be evaluated and monitored during treatment. The aim of this article is to describe a case report of a patient presenting trastuzumab-associated cardiotoxicity and the importance of monitoring and early identification of cardiotoxicity through echocardiography (ECHO). Case report: A 63-year-old female patient, hypertensive, obese, with breast cancer, presented trastuzumab-associated cardiotoxicity, reduced left ventricular ejection fraction (LVEF), who developed diabetes after the treatment. The patient underwent regular echocardiography follow-up during treatment and this process was essential for early detection and appropriate management of trastuzumab-associated cardiotoxicity. An algorithm was used to determine the causality. Conclusion: This study shows the importance of LVEF follow-up with ECHO in patients undergoing cardiotoxic chemotherapy, and the monitoring of possible metabolic changes after oncologic treatment. |
id |
INCA-1_8b5a834e6053d00ca5d925fb35ec69d3 |
---|---|
oai_identifier_str |
oai:rbc.inca.gov.br:article/570 |
network_acronym_str |
INCA-1 |
network_name_str |
Revista Brasileira de Cancerologia (Online) |
repository_id_str |
|
spelling |
The Importance of Early Monitoring and Identification of Cardiotoxicity of Trastuzumab Treatment in Breast Cancer: Case ReportLa Importancia del Monitoreo y de la Identificación Temprano de la Cardiotoxicidad del Tratamiento con Trastuzumab en el Cáncer de Mama: Informe de CasoA Importância do Monitoramento e da Identificação Precoce de Cardiotoxicidade do Tratamento com Trastuzumabe no Câncer de Mama: Relato de CasoCardiotoxicidadeNeoplasias da MamaTrastuzumabTratamento FarmacológicoCardiotoxicityBreast NeoplasmsTrastuzumabDrug TherapyCardiotoxicidadNeoplasias de la MamaTrastuzumabTratamiento FarmacológicoIntroduction: Breast cancer represents the most common neoplasm among women, with elevated morbimortality. With the appearance of new drugs, there has been an increase of global survival; however, trastuzumab, a monoclonal antibody used in the treatment, may promote cardiotoxicity that should be evaluated and monitored during treatment. The aim of this article is to describe a case report of a patient presenting trastuzumab-associated cardiotoxicity and the importance of monitoring and early identification of cardiotoxicity through echocardiography (ECHO). Case report: A 63-year-old female patient, hypertensive, obese, with breast cancer, presented trastuzumab-associated cardiotoxicity, reduced left ventricular ejection fraction (LVEF), who developed diabetes after the treatment. The patient underwent regular echocardiography follow-up during treatment and this process was essential for early detection and appropriate management of trastuzumab-associated cardiotoxicity. An algorithm was used to determine the causality. Conclusion: This study shows the importance of LVEF follow-up with ECHO in patients undergoing cardiotoxic chemotherapy, and the monitoring of possible metabolic changes after oncologic treatment.Introducción: El cáncer de mama representa el cáncer más común entre las mujeres, con alta morbilidad y mortalidad. Con el advenimiento de nuevos medicamentos, ha habido un aumento en la supervivencia general, sin embargo, trastuzumab, un anticuerpo monoclonal utilizado en el tratamiento, puede promover la cardiotoxicidad, que debe evaluarse y monitorearse durante el tratamiento. El objetivo de este trabajo es describir un informe de caso de un paciente que presenta cardiotoxicidad asociada con el uso de trastuzumab y la importancia del monitoreo y la identificación temprana de la cardiotoxicidad a través del monitoreo ecocardiográfico (ECHO). Relato del caso: Una paciente de 63 años, hipertensa, obesa, con cáncer de mama, tenía cardiotoxicidad asociada con trastuzumab, fracción de eyección ventricular izquierda (FEVI) reducida y diabetes después del tratamiento. El paciente se sometió a un seguimiento ecocardiográfico regular durante el tratamiento y fue el proceso fundamental para la detección temprana y el manejo adecuado de la cardiotoxicidad asociada con el uso de trastuzumab. Se utilizó un algoritmo para determinar la causalidad. Conclusión: Este estudio muestra la importancia del seguimiento ECHO de la FEVI en pacientes sometidos a quimioterapia cardiotóxica, y el monitoreo de posibles cambios metabólicos después del tratamiento del cáncer.Introdução: O câncer de mama representa a neoplasia mais frequente entre as mulheres, com elevada morbimortalidade. Com o advento de novos medicamentos, houve um aumento na sobrevida global; entretanto, o trastuzumabe, um anticorpo monoclonal utilizado no tratamento, pode promover cardiotoxicidade, que deve ser avaliada e monitorada durante o tratamento. O objetivo deste artigo é descrever um relato de caso de paciente que apresentou cardiotoxicidade associada ao uso de trastuzumabe e a importância do monitoramento e da identificação precoce da cardiotoxicidade por meio do monitoramento pelo ecocardiograma (ECO). Relato do caso: Paciente, sexo feminino, 63 anos, hipertensa, obesa, com câncer de mama, apresentou cardiotoxicidade associada ao uso de trastuzumabe, com redução da fração de ejeção do ventrículo esquerdo (FEVE) e desenvolveu diabetes após o tratamento. A paciente fez acompanhamento regular pelo ECO durante o tratamento, tendo sido esse processo fundamental para a detecção precoce e o manejo adequado da cardiotoxicidade associada ao uso do trastuzumabe. Foi utilizado um algoritmo na determinação da causalidade. Conclusão: Este estudo mostra a importância do acompanhamento da FEVE pelo ECO em pacientes submetidas à quimioterapia cardiotóxica, e do monitoramento de possíveis alterações metabólicas após o tratamento oncológico.INCA2019-12-12info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionRelato de Casoapplication/pdfapplication/pdfhttps://rbc.inca.gov.br/index.php/revista/article/view/57010.32635/2176-9745.RBC.2019v65n3.570Revista Brasileira de Cancerologia; Vol. 65 No. 3 (2019): July/Aug./Sept.; e-10570Revista Brasileira de Cancerologia; Vol. 65 Núm. 3 (2019): jul./agosto/sept.; e-10570Revista Brasileira de Cancerologia; v. 65 n. 3 (2019): jul./ago./set.; e-105702176-9745reponame:Revista Brasileira de Cancerologia (Online)instname:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)instacron:INCAporenghttps://rbc.inca.gov.br/index.php/revista/article/view/570/494https://rbc.inca.gov.br/index.php/revista/article/view/570/611Copyright (c) 2019 Revista Brasileira de Cancerologiainfo:eu-repo/semantics/openAccessMarques Soares Valente, PatriciaClaudino Pires de Souza, WalterPinho Braga, Eduardo Ferreira Neves, ThamiresLopes da Silva, Thamiresde Andrade Martins, WolneyRodrigues de Castilho, Selma2021-11-29T20:03:33Zoai:rbc.inca.gov.br:article/570Revistahttps://rbc.inca.gov.br/index.php/revistaPUBhttps://rbc.inca.gov.br/index.php/revista/oairbc@inca.gov.br0034-71162176-9745opendoar:2021-11-29T20:03:33Revista Brasileira de Cancerologia (Online) - Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)false |
dc.title.none.fl_str_mv |
The Importance of Early Monitoring and Identification of Cardiotoxicity of Trastuzumab Treatment in Breast Cancer: Case Report La Importancia del Monitoreo y de la Identificación Temprano de la Cardiotoxicidad del Tratamiento con Trastuzumab en el Cáncer de Mama: Informe de Caso A Importância do Monitoramento e da Identificação Precoce de Cardiotoxicidade do Tratamento com Trastuzumabe no Câncer de Mama: Relato de Caso |
title |
The Importance of Early Monitoring and Identification of Cardiotoxicity of Trastuzumab Treatment in Breast Cancer: Case Report |
spellingShingle |
The Importance of Early Monitoring and Identification of Cardiotoxicity of Trastuzumab Treatment in Breast Cancer: Case Report Marques Soares Valente, Patricia Cardiotoxicidade Neoplasias da Mama Trastuzumab Tratamento Farmacológico Cardiotoxicity Breast Neoplasms Trastuzumab Drug Therapy Cardiotoxicidad Neoplasias de la Mama Trastuzumab Tratamiento Farmacológico |
title_short |
The Importance of Early Monitoring and Identification of Cardiotoxicity of Trastuzumab Treatment in Breast Cancer: Case Report |
title_full |
The Importance of Early Monitoring and Identification of Cardiotoxicity of Trastuzumab Treatment in Breast Cancer: Case Report |
title_fullStr |
The Importance of Early Monitoring and Identification of Cardiotoxicity of Trastuzumab Treatment in Breast Cancer: Case Report |
title_full_unstemmed |
The Importance of Early Monitoring and Identification of Cardiotoxicity of Trastuzumab Treatment in Breast Cancer: Case Report |
title_sort |
The Importance of Early Monitoring and Identification of Cardiotoxicity of Trastuzumab Treatment in Breast Cancer: Case Report |
author |
Marques Soares Valente, Patricia |
author_facet |
Marques Soares Valente, Patricia Claudino Pires de Souza, Walter Pinho Braga, Eduardo Ferreira Neves, Thamires Lopes da Silva, Thamires de Andrade Martins, Wolney Rodrigues de Castilho, Selma |
author_role |
author |
author2 |
Claudino Pires de Souza, Walter Pinho Braga, Eduardo Ferreira Neves, Thamires Lopes da Silva, Thamires de Andrade Martins, Wolney Rodrigues de Castilho, Selma |
author2_role |
author author author author author author |
dc.contributor.author.fl_str_mv |
Marques Soares Valente, Patricia Claudino Pires de Souza, Walter Pinho Braga, Eduardo Ferreira Neves, Thamires Lopes da Silva, Thamires de Andrade Martins, Wolney Rodrigues de Castilho, Selma |
dc.subject.por.fl_str_mv |
Cardiotoxicidade Neoplasias da Mama Trastuzumab Tratamento Farmacológico Cardiotoxicity Breast Neoplasms Trastuzumab Drug Therapy Cardiotoxicidad Neoplasias de la Mama Trastuzumab Tratamiento Farmacológico |
topic |
Cardiotoxicidade Neoplasias da Mama Trastuzumab Tratamento Farmacológico Cardiotoxicity Breast Neoplasms Trastuzumab Drug Therapy Cardiotoxicidad Neoplasias de la Mama Trastuzumab Tratamiento Farmacológico |
description |
Introduction: Breast cancer represents the most common neoplasm among women, with elevated morbimortality. With the appearance of new drugs, there has been an increase of global survival; however, trastuzumab, a monoclonal antibody used in the treatment, may promote cardiotoxicity that should be evaluated and monitored during treatment. The aim of this article is to describe a case report of a patient presenting trastuzumab-associated cardiotoxicity and the importance of monitoring and early identification of cardiotoxicity through echocardiography (ECHO). Case report: A 63-year-old female patient, hypertensive, obese, with breast cancer, presented trastuzumab-associated cardiotoxicity, reduced left ventricular ejection fraction (LVEF), who developed diabetes after the treatment. The patient underwent regular echocardiography follow-up during treatment and this process was essential for early detection and appropriate management of trastuzumab-associated cardiotoxicity. An algorithm was used to determine the causality. Conclusion: This study shows the importance of LVEF follow-up with ECHO in patients undergoing cardiotoxic chemotherapy, and the monitoring of possible metabolic changes after oncologic treatment. |
publishDate |
2019 |
dc.date.none.fl_str_mv |
2019-12-12 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Relato de Caso |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://rbc.inca.gov.br/index.php/revista/article/view/570 10.32635/2176-9745.RBC.2019v65n3.570 |
url |
https://rbc.inca.gov.br/index.php/revista/article/view/570 |
identifier_str_mv |
10.32635/2176-9745.RBC.2019v65n3.570 |
dc.language.iso.fl_str_mv |
por eng |
language |
por eng |
dc.relation.none.fl_str_mv |
https://rbc.inca.gov.br/index.php/revista/article/view/570/494 https://rbc.inca.gov.br/index.php/revista/article/view/570/611 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2019 Revista Brasileira de Cancerologia info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2019 Revista Brasileira de Cancerologia |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
INCA |
publisher.none.fl_str_mv |
INCA |
dc.source.none.fl_str_mv |
Revista Brasileira de Cancerologia; Vol. 65 No. 3 (2019): July/Aug./Sept.; e-10570 Revista Brasileira de Cancerologia; Vol. 65 Núm. 3 (2019): jul./agosto/sept.; e-10570 Revista Brasileira de Cancerologia; v. 65 n. 3 (2019): jul./ago./set.; e-10570 2176-9745 reponame:Revista Brasileira de Cancerologia (Online) instname:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA) instacron:INCA |
instname_str |
Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA) |
instacron_str |
INCA |
institution |
INCA |
reponame_str |
Revista Brasileira de Cancerologia (Online) |
collection |
Revista Brasileira de Cancerologia (Online) |
repository.name.fl_str_mv |
Revista Brasileira de Cancerologia (Online) - Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA) |
repository.mail.fl_str_mv |
rbc@inca.gov.br |
_version_ |
1797042244555898880 |